CalciMedica Reports Q1 Net Income Driven by Non-Cash Gains; Discloses Going Concern and Lost Debt Tranches

summarizeSummary

CalciMedica reported a Q1 2026 net income of $5.0 million, primarily due to non-cash fair value adjustments of warrant and promissory note liabilities. The company disclosed substantial doubt about its ability to continue as a going concern, with cash runway only into Q4 2026, and confirmed the loss of $22.5 million in previously available debt tranches.

check_boxKey Events

• Q1 2026 Net Income Driven by Non-Cash Gains

  CalciMedica reported a net income of $5.0 million for Q1 2026, a significant improvement from a net loss of $5.0 million in Q1 2025. This income was largely due to a $10.8 million non-cash gain from fair value adjustments to warrant and promissory note liabilities.

• Substantial Doubt About Going Concern

  Management expressed substantial doubt about the company's ability to continue as a going concern, with current cash and cash equivalents of $8.2 million expected to fund operations only into the fourth quarter of 2026.

• Lost Access to $22.5M in Debt Tranches

  Tranche 2 ($7.5 million) and Tranche 3 ($15.0 million) of a $32.5 million growth capital loan are no longer available to the company due to the pause in the KOURAGE clinical trial, severely impacting future liquidity.

• Ongoing Nasdaq Delisting Risk

  The company remains non-compliant with Nasdaq's minimum market value and minimum bid price requirements, facing potential delisting by September 2026.

auto_awesomeAnalysis

CalciMedica's reported Q1 2026 net income of $5.0 million is primarily an accounting artifact, stemming from a $10.8 million non-cash gain due to fair value adjustments of warrant and promissory note liabilities. This masks a precarious financial situation, as the company explicitly states 'substantial doubt about its ability to continue as a going concern.' With only $8.2 million in cash and cash equivalents, the company projects its runway only into the fourth quarter of 2026. A critical blow to its financing strategy is the confirmed unavailability of Tranche 2 ($7.5 million) and Tranche 3 ($15.0 million) of a $32.5 million growth capital loan, totaling $22.5 million, due to the pause in the KOURAGE clinical trial. This significantly limits immediate liquidity options. Compounding these issues are ongoing Nasdaq delisting risks for failing to meet minimum market value and bid price requirements. While a new $125.0 million shelf registration provides potential future capital access, the immediate financial challenges are severe and pose a significant threat to the company's operations and clinical development programs.